Jefferies Financial Group Weighs in on Dyne Therapeutics, Inc.’s Q2 2022 Earnings (NASDAQ:DYN)

Dyne Therapeutics, Inc. (NASDAQ:DYNGet Rating) – Equities researchers at Jefferies Financial Group increased their Q2 2022 earnings per share (EPS) estimates for Dyne Therapeutics in a research report issued on Monday, May 2nd. Jefferies Financial Group analyst E. Yang now expects that the company will post earnings per share of ($0.88) for the quarter, up from their prior forecast of ($1.14). Jefferies Financial Group also issued estimates for Dyne Therapeutics’ Q3 2022 earnings at ($0.98) EPS, Q4 2022 earnings at ($1.09) EPS, FY2022 earnings at ($3.64) EPS, FY2023 earnings at ($4.24) EPS, FY2024 earnings at ($4.69) EPS, FY2025 earnings at ($4.72) EPS and FY2026 earnings at ($4.68) EPS.

Dyne Therapeutics (NASDAQ:DYNGet Rating) last announced its quarterly earnings results on Monday, May 2nd. The company reported ($0.69) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.88) by $0.19.

A number of other brokerages also recently commented on DYN. Zacks Investment Research raised shares of Dyne Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 16th. Stifel Nicolaus reissued a “buy” rating and issued a $29.00 price objective on shares of Dyne Therapeutics in a research note on Friday, March 11th.

Shares of NASDAQ:DYN opened at $8.34 on Thursday. Dyne Therapeutics has a 12 month low of $6.39 and a 12 month high of $22.92. The company has a 50-day moving average price of $9.01 and a 200 day moving average price of $10.67.

Several institutional investors have recently bought and sold shares of DYN. Morgan Stanley raised its stake in shares of Dyne Therapeutics by 3,595.2% during the second quarter. Morgan Stanley now owns 4,656 shares of the company’s stock valued at $98,000 after acquiring an additional 4,530 shares in the last quarter. Invesco Ltd. bought a new stake in shares of Dyne Therapeutics during the second quarter valued at approximately $209,000. SG Americas Securities LLC bought a new stake in shares of Dyne Therapeutics during the third quarter valued at approximately $1,158,000. BlackRock Inc. raised its stake in shares of Dyne Therapeutics by 0.8% during the third quarter. BlackRock Inc. now owns 1,988,152 shares of the company’s stock valued at $32,288,000 after acquiring an additional 15,944 shares in the last quarter. Finally, Citigroup Inc. raised its stake in shares of Dyne Therapeutics by 101.9% during the third quarter. Citigroup Inc. now owns 3,791 shares of the company’s stock valued at $62,000 after acquiring an additional 1,913 shares in the last quarter. 76.28% of the stock is owned by hedge funds and other institutional investors.

In other Dyne Therapeutics news, insider Wildon Farwell sold 5,617 shares of the firm’s stock in a transaction dated Wednesday, March 2nd. The shares were sold at an average price of $8.56, for a total value of $48,081.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 6,690 shares of company stock valued at $57,449. 42.67% of the stock is owned by insiders.

Dyne Therapeutics Company Profile (Get Rating)

Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Read More

Earnings History and Estimates for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.